|By Marketwired .||
|December 1, 2016 08:17 AM EST|
HONG KONG, CHINA -- (Marketwired) -- 12/01/16 -- Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group"; HKEx code: 690) has today announced that it has signed a multiple drug co-development deal with Beijing Sun-Novo Pharmaceutical Research Co., Ltd. ("Beijing Sun-Novo"), a China-based company engaged in research and development (R&D), manufacturing and commercialization of pharmaceutical products, to extend Uni-Bio's current R&D capabilities in small molecule drug development. This cooperation includes co-development of various oral anti-diabetes drugs ("OAD") to build a comprehensive diabetes treatment portfolio for the Group, which would represent an all-encompassing strategy in satisfying the unmet needs in treatment of this increasingly prevalent disease.
The first co-development project of the two companies is to develop high quality Acarbose tablets for treatment of Type 2 diabetes, an emerging and increasingly important diabetes treatment in China. Under this collaboration, Beijing Sun-Novo is to be responsible for completing the chemistry, manufacturing and control (CMC) processes and the bioequivalence study of Acarbose, as well as transferring the production technology to Uni-Bio Science's subsidiary. On the other hand, Uni-Bio Science is to apply for drug licenses from the China Food and Drug Administration with support from Beijing Sun-Novo and commercialize the product once it is approved. The project is targeted to start in 2017 and launch sales in the market around 2020 to 2021.
Mr. Kingsley Leung, Executive Director of Uni-Bio Science, said, "Our cooperation with Beijing Sun-Novo is an exciting opportunity to realize our goal quickly of becoming an industry-leading expert in diabetes management. With the incidence of diabetes reaching epidemic levels in China and across the world, there is a need for a wider range of treatment options to better manage this long-term chronic condition. This multiple co-development deal can strengthen our R&D capabilities and enhance our current positioning of our portfolio to meet the increasing market demand. We are planning to collaborate on various OAD to satisfy unmet medical needs, and Acarbose is another important component of a comprehensive diabetes product strategy targeting 1st-to-4th line of treatment within the Chinese treatment guideline. As this collaboration progresses, we hope to develop two or more OADs that can further complement our existing diabetes portfolio of Mitiglinide and rExtendin-4 (Uni-E4)."
Mr. Li Qian, Chairman of Beijing Sun-Novo, said, "Uni-Bio Science and Beijing Sun-Novo, as strategic partners, will strive to introduce medical innovations that improve treatment efficacy and the quality of living of diabetics in China and also to cooperate in depth on diabetes, dermatological and ophthalmological products in the future through upholding the principles of working as one and aiming for win-win outcomes. With a seasoned R&D team, the company has developed a sound quality testing and control system, forged a complete industry chain integrating production operations and aligned R&D to ensure efficient cooperation in compliance with all rules and regulations. We believe the complementary partnership will help enhance the value of Beijing Sun-Novo and boost our strengths in innovation and R&D while injecting new impetus into Uni-Bio Science, and together we may welcome a new era for pharmaceuticals as we both benefit. We will strive to build a new platform for furthering cooperation, development and exchanges in areas including resources allocation, business integration, workflow and service coverage, thereby generating synergies and improving innovation capabilities, for the goal of achieving strategic breakthroughs in development. "
Acarbose is an oral anti-diabetic drug which belongs to the Alpha-Glucosidase Inhibitors ("AGI") class. It is used to treat Type 2 diabetes and is reimbursed under the National Reimbursement Drug List ("NRDL"). In terms of diabetes treatment, AGI is important for the early stage of diabetes. It targets patients with pre-diabetes condition who need to be treated early, and those with post prandial hyperglycemia under control.
According to IMS China Data, AGI is uniquely positioned within China's diabetes guidelines, maintaining around 18% of China's anti-diabetes drug market in 2012 to 2015, which is especially effective for Asian patients with a high-carbohydrate diet content. Acarbose has the largest market share at 87.8% in China's AGI market in 2015, which represents a market size of RMB3.4 billion. Meanwhile, the domestic sales revenue of Acarbose increased at a compound annual growth rate of 10.3% from 2012 to 2015, which clearly shows the enormous potential and promising growth opportunities of the drug in the market.
About Uni-Bio Science Group Limited (SEHK: 0690)
Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development center located in Dongguan, PRC is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with CFDA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group is focused on the development of novel treatments addressing the therapeutic areas of diabetes, ophthalmology and dermatology.
About Beijing Sun-Novo Pharmaceutical Research Co., Ltd.
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. is a national high-tech company with international ISO9001:2008 quality management certification. With a 1,200 sq.m. laboratory and an R&D team comprising more than 70 professionals, the Company is well-positioned as a high-tech enterprise focusing on the R&D of pharmaceutical technologies and Active Pharmaceutical Ingredient ("API") intermediate trading. It strives to conduct innovative research and provide contract services in relation to pharmaceutical technologies riding on its advantages in R&D for new medicines and a commercialization model. The Company also has its own professional team and standardized laboratory for conducting R&D of new medicines, industrial production and API trading. Its core businesses cover R&D for chemical formulas of medicines, transfer of expertise and cooperation, API intermediate production and trading, clinical research services and import registration.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=3086775
Microservices are a very exciting architectural approach that many organizations are looking to as a way to accelerate innovation. Microservices promise to allow teams to move away from monolithic "ball of mud" systems, but the reality is that, in the vast majority of organizations, different projects and technologies will continue to be developed at different speeds. How to handle the dependencies between these disparate systems with different iteration cycles? Consider the "canoncial problem" ...
Mar. 28, 2017 06:00 AM EDT Reads: 8,879
As businesses adopt functionalities in cloud computing, it’s imperative that IT operations consistently ensure cloud systems work correctly – all of the time, and to their best capabilities. In his session at @BigDataExpo, Bernd Harzog, CEO and founder of OpsDataStore, will present an industry answer to the common question, “Are you running IT operations as efficiently and as cost effectively as you need to?” He will expound on the industry issues he frequently came up against as an analyst, and...
Mar. 28, 2017 06:00 AM EDT Reads: 4,276
Why do your mobile transformations need to happen today? Mobile is the strategy that enterprise transformation centers on to drive customer engagement. In his general session at @ThingsExpo, Roger Woods, Director, Mobile Product & Strategy – Adobe Marketing Cloud, covered key IoT and mobile trends that are forcing mobile transformation, key components of a solid mobile strategy and explored how brands are effectively driving mobile change throughout the enterprise.
Mar. 28, 2017 06:00 AM EDT Reads: 2,941
After more than five years of DevOps, definitions are evolving, boundaries are expanding, ‘unicorns’ are no longer rare, enterprises are on board, and pundits are moving on. Can we now look at an evolution of DevOps? Should we? Is the foundation of DevOps ‘done’, or is there still too much left to do? What is mature, and what is still missing? What does the next 5 years of DevOps look like? In this Power Panel at DevOps Summit, moderated by DevOps Summit Conference Chair Andi Mann, panelists l...
Mar. 28, 2017 05:00 AM EDT Reads: 9,879
In their Live Hack” presentation at 17th Cloud Expo, Stephen Coty and Paul Fletcher, Chief Security Evangelists at Alert Logic, provided the audience with a chance to see a live demonstration of the common tools cyber attackers use to attack cloud and traditional IT systems. This “Live Hack” used open source attack tools that are free and available for download by anybody. Attendees learned where to find and how to operate these tools for the purpose of testing their own IT infrastructure. The...
Mar. 28, 2017 04:45 AM EDT Reads: 7,463
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
Mar. 28, 2017 02:30 AM EDT Reads: 2,019
My team embarked on building a data lake for our sales and marketing data to better understand customer journeys. This required building a hybrid data pipeline to connect our cloud CRM with the new Hadoop Data Lake. One challenge is that IT was not in a position to provide support until we proved value and marketing did not have the experience, so we embarked on the journey ourselves within the product marketing team for our line of business within Progress. In his session at @BigDataExpo, Sum...
Mar. 28, 2017 02:15 AM EDT Reads: 3,091
The modern software development landscape consists of best practices and tools that allow teams to deliver software in a near-continuous manner. By adopting a culture of automation, measurement and sharing, the time to ship code has been greatly reduced, allowing for shorter release cycles and quicker feedback from customers and users. Still, with all of these tools and methods, how can teams stay on top of what is taking place across their infrastructure and codebase? Hopping between services a...
Mar. 28, 2017 02:15 AM EDT Reads: 9,900
Virtualization over the past years has become a key strategy for IT to acquire multi-tenancy, increase utilization, develop elasticity and improve security. And virtual machines (VMs) are quickly becoming a main vehicle for developing and deploying applications. The introduction of containers seems to be bringing another and perhaps overlapped solution for achieving the same above-mentioned benefits. Are a container and a virtual machine fundamentally the same or different? And how? Is one techn...
Mar. 28, 2017 02:15 AM EDT Reads: 3,106
SYS-CON Events announced today that MobiDev, a client-oriented software development company, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software company that develops and delivers turn-key mobile apps, websites, web services, and complex softw...
Mar. 28, 2017 02:00 AM EDT Reads: 3,890
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
Mar. 28, 2017 01:00 AM EDT Reads: 2,342
What sort of WebRTC based applications can we expect to see over the next year and beyond? One way to predict development trends is to see what sorts of applications startups are building. In his session at @ThingsExpo, Arin Sime, founder of WebRTC.ventures, will discuss the current and likely future trends in WebRTC application development based on real requests for custom applications from real customers, as well as other public sources of information,
Mar. 28, 2017 12:45 AM EDT Reads: 982
Interoute has announced the integration of its Global Cloud Infrastructure platform with Rancher Labs’ container management platform, Rancher. This approach enables enterprises to accelerate their digital transformation and infrastructure investments. Matthew Finnie, Interoute CTO commented “Enterprises developing and building apps in the cloud and those on a path to Digital Transformation need Digital ICT Infrastructure that allows them to build, test and deploy faster than ever before. The int...
Mar. 28, 2017 12:00 AM EDT Reads: 1,247
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, discussed how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a practic...
Mar. 28, 2017 12:00 AM EDT Reads: 8,378
ChatOps is an emerging topic that has led to the wide availability of integrations between group chat and various other tools/platforms. Currently, HipChat is an extremely powerful collaboration platform due to the various ChatOps integrations that are available. However, DevOps automation can involve orchestration and complex workflows. In his session at @DevOpsSummit at 20th Cloud Expo, Himanshu Chhetri, CTO at Addteq, will cover practical examples and use cases such as self-provisioning infra...
Mar. 27, 2017 11:30 PM EDT Reads: 3,063